fibrinogen complex

Overview

The fibrinogen complex refers to the circulating plasma glycoprotein system centered on fibrinogen, a key component of hemostasis and thrombosis. In normal physiology, fibrinogen is converted by thrombin into fibrin, which polymerizes to form the structural basis of a blood clot. Because of this central role, fibrinogen is closely linked to coagulation, platelet aggregation, wound repair, and inflammatory responses.

Clinically, fibrinogen is widely used as a biomarker of coagulation status and systemic inflammation. Elevated fibrinogen is commonly associated with chronic inflammatory states and prothrombotic risk, while reduced levels may reflect consumption or impaired synthesis in severe illness or bleeding disorders. In recent biomedical research, fibrinogen has been examined in contexts ranging from acute ischemic stroke and severe trauma to COVID-19, Crohn's disease, polycystic ovary syndrome, and device hemocompatibility testing.

Focus of Latest Publications

Recent research on fibrinogen complex spans diagnostic applications, therapeutic targeting, and tissue engineering innovations. Fibrinogen levels have emerged as a valuable clinical biomarker across multiple disease contexts. In pediatric nephrotic syndrome, elevated serum fibrinogen correlated independently with respiratory tract infection risk, with combined measurement of fibrinogen and urinary α1-microglobulin demonstrating superior predictive accuracy (AUC >0.917) for early risk stratification. Similarly, in severe trauma patients, fibrinogen trajectory alongside platelet and D-dimer levels provided prognostic information for venous thromboembolism prediction. Fibrinogen has also been identified as a circulating protein marker in smoking-induced chronic obstructive pulmonary disease, predicting disease severity and exacerbation risk.

The association between systemic fibrinogen elevation and pathological coagulation has been documented across multiple acute and chronic conditions. In severe COVID-19, elevated fibrinogen levels showed statistically significant associations with coagulopathy parameters, correlating with the disease's inflammatory-coagulation crosstalk. Abdominal adiposity—particularly visceral fat accumulation—was associated with increased plasma fibrinogen and related prothrombotic coagulation markers, suggesting a metabolic link to thrombotic disease risk. In polycystic ovary syndrome, fibrinogen emerged as a differentially expressed protein with diagnostic potential, validated through ELISA-based proteomic approaches.

Therapeutic strategies targeting fibrinogen are advancing on two fronts. Anticoagulant research is exploring fibrinogen and fibrin as novel intervention targets to reduce thrombotic disease burden while potentially improving the safety profile of current anticoagulants beyond direct oral anticoagulants. Concurrently, fibrinogen derivatives are being engineered for tissue regeneration; methacrylated fibrinogen (FibMA) was incorporated into interpenetrating polymer network hydrogels with photochemically reinforced fibrillar architectures, achieving precise control over mechanical properties and supporting robust three-dimensional cell growth with reduced compaction, demonstrating dual potential as both a therapeutic target and a biomaterial scaffold. In acute ischemic stroke, baseline fibrinogen levels were evaluated for their impact on the differential efficacy and safety profiles of distinct thrombolytic agents, reflecting the complex role of fibrinogen in both pathophysiology and treatment response.

Key Publications

NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42402858)
NEWJul Combining Supramolecular and Covalent Chemistry to Form Reinforced Fibrillar Network Hydrogels From Fibrinogen Derivatives. (Journal of biomedical materials research. Part A, 2026, PMID 42383387): "These interpenetrating polymer network (IPN) hydrogels were formed by thrombin-mediated activation of fibrinogen to initiate supramolecular fibrin assembly (fibrillogenesis), followed by light-activated covalent crosslinking of FibMA (photopolymerization)."
Jul The Trajectories of Platelet, Fibrinogen, and D-dimer in Severe Trauma Patients and Their Value in Predicting Venous Thromboembolism: A Retrospective Study. (Dimensions of critical care nursing : DCCN, 2026, PMID 42207594): "Platelet count (PLT), fibrinogen level (FIB), and D-dimer level are important coagulation indicators; however, few studies have described their trajectory in ST and assessed predictive value for VTE in clinical and nursing practice."
May Abdominal Fat Measures Are Associated With Sex-Specific Prothrombotic Changes in Middle-Aged Adults. (Arteriosclerosis, thrombosis, and vascular biology, 2026, PMID 42131917): "plasma levels of factor (F) VIII, FIX, FXI, fibrinogen, and thrombin generation (endogenous thrombin potential and peak thrombin)"
May Efficacy and Safety of Reteplase Versus Alteplase in Acute Ischemic Stroke Based on Fibrinogen Levels: The RAISE Trial Subgroup. (Journal of the American Heart Association, 2026, PMID 42089199): "Using data from the RAISE (Reteplase Versus Alteplase for Acute Ischemic Stroke) trial, we aimed to investigate the impact of differences in baseline plasma fibrinogen levels on the efficacy and safety of reteplase versus alteplase within 4.5 hours of acute ischemic stroke symptom onset."
May Cross-talk between inflammation and coagulation in severe COVID-19: Association of leptin and classical pro-inflammatory markers with coagulation disorders in a single-center observational cohort study. (Medicine, 2026, PMID 42065184): "We found statistically significant associations between blood levels of various biomarkers including leptin, IL-6, ferritin, neutrophil-lymphocyte ratio, C-reactive protein, fibrinogen, erythrocyte sedimentation rate and lactate dehydrogenase and the presence of coagulopathy, as indicated by the Pearson Chi-Square and Likelihood Ratio tests."
Jul ELISA-based validation of differentially expressed Fibrinogen, S100A9, SERPINA3 and SERPINA6 proteins in Polycystic Ovary Syndrome (PCOS). (Steroids, 2026, PMID 42034305): "we validated four serum proteins highlighted in earlier nLC-MS/MS based proteomic work, namely; Fibrinogen, S100A9, SERPINA3 and SERPINA6."
Apr Multi-omics biomarker detection in smoking induced COPD. (Clinica chimica acta; international journal of clinical chemistry, 2026, PMID 41605376): "Reproducible circulating protein markers identified in proteomic studies include surfactant protein D (SP-D), club cell secretory protein (CC16), fibrinogen, and inflammatory cytokines, which predict disease severity, risk of exacerbation, and mortality."
Apr Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants. (Journal of thrombosis and haemostasis : JTH, 2026, PMID 41485707): "This is followed by analysis of options for the therapeutic targeting of fibrin or fibrinogen and FXIII."